# Sotio

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Sotio
> Markdown URL: https://mediated.wiki/source/Sotio.md
> Source: https://en.wikipedia.org/wiki/Sotio
> Source revision: 1321303965
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

**SOTIO Biotech**[1] is a clinical-stage [biotechnology](/source/Biotechnology) company focused on research and development of next-generation [cancer](/source/Cancer) immunotherapies, with operations in [Europe](/source/Europe) and [North America](/source/North_America).[2] The company has clinical programs which include a [superagonist](/source/Superagonist) of the immuno-oncology target [IL-15](/source/Interleukin_15) and new generation of potent and stable [antibody-drug conjugates](/source/Antibody-drug_conjugate) (ADCs).[3]

## Founding

The company was founded in 2010 and in 2012 became part of [PPF Group](/source/PPF_(company)), established by [Petr Kellner](/source/Petr_Kellner).[4] The CEO of the company is Radek Špíšek, who has been with the company since its beginning, initially functioning as Chief Scientific Officer.[5]

## Operations

SOTIO operates globally, with offices in [Prague](/source/Prague), [Czech Republic](/source/Czech_Republic), [Basel](/source/Basel), [Switzerland](/source/Switzerland) and [Boston](/source/Boston), [USA](/source/United_States).[6]

## Pipeline

SOTIO is currently developing and testing multiple [oncology](/source/Oncology) products at different stages of preclinical and clinical development.[7]

### Immunocytokines

SOTIO is developing SOT201, an immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody. As a PD-1-targeted and cis-acting attenuated IL-15 agonist, SOT201 is designed to preferentially activate PD-1+CD8+ T cells, inducing superior anti-tumor effects and reinvigorating exhausted CD8+ T cells in PD-1 sensitive and resistant tumors. SOT201 entered the clinic in May 2024 with the Phase 1 VICTORIA-01 clinical trial.[8]

### Antibody Drug Conjugates

SOTIO is advancing a pipeline of antibody-drug conjugates (ADCs) to treat solid tumors through collaborations with Biocytogen, [Synaffix](/source/Synaffix), LigaChem, and [NBE-Therapeutics](/source/NBE-Therapeutics).[9][10] Its two most advanced ADC therapeutic candidates are SOT109, an anti-CDH17 ADC in development for the treatment of colorectal cancer, and SOT106, an anti-LRRC15 ADC in development for the treatment of LRRC15+ sarcomas and other solid tumors.[11]

## Investments

SOTIO has its own scientific research and development and also collaborates with other partners. In recent years, SOTIO and PPF have focused also on investing in biotechnology companies developing innovative anticancer treatments in Europe and the US.

At the end of 2020, PPF sold its stake in [NBE-Therapeutics](/source/NBE-Therapeutics), a company developing innovative [ADC](/source/Antibody%E2%80%93drug_conjugate) products for the treatment of solid tumours, to the leading global pharmaceutical company [Boehringer Ingelheim](/source/Boehringer_Ingelheim). This deal, the largest of its kind to be witnessed in Europe in ten years, showed the value of the ADCs that SOTIO maintains in its portfolio and that it continues to develop.

SOTIO is also managing PPF's investments in biotechnology companies [Autolus Therapeutics](/source/Autolus_Therapeutics) and [Cellestia Biotech](/source/Cellestia_Biotech).[12]

## References

1. SOTIO, Biotech. ["The Company"](https://sotio.com/about-us/the-company). *Sotio*. Retrieved 2022-03-15.

1. McKenzie, Heather. ["An In-Depth Look at Innovation on Cancer Research Day"](https://www.biospace.com/article/an-in-depth-look-at-innovation-in-cancer-research-/). *BioSpace*. Retrieved 2022-03-15.

1. Pillar, Matthew. ["SOTIO's Quest To Build A Global Biopharma"](https://www.bioprocessonline.com/doc/sotio-s-quest-to-build-a-global-biopharma-0001). *bioprocessonline.com*. Retrieved 2022-03-15.

1. ["SOTIO Arms Dendritic Cells for Immunotherapy Against Cancer"](https://wxpress.wuxiapptec.com/sotio-arms-dendritic-cells-for-immunotherapy-against-cancer/). *WuXi XPress*. Retrieved 2022-03-15.

1. ["Leadership"](https://sotio.com/about-us/leadership). *Sotio*. Retrieved 2022-03-15.

1. Kenety, Brian (2019-07-11). ["Czech PPF Group biotech firms begin trials to extend lives of cancer patients"](https://english.radio.cz/czech-ppf-group-biotech-firms-begin-trials-extend-lives-cancer-patients-8126262). *Radio Prague International*. Retrieved 2022-03-15.

1. ["SOTIO Biotech Pipeline"](https://sotio.com/pipeline/sotio-biotech-pipeline). *Sotio*. Retrieved 2022-03-15.

1. s.r.o, ANDWEB. ["SOTIO Showcases New Data on SOT201 Immunocytokine, VICTORIA-01 Clinical Study, and BOXR CAR-T Advancements at 2024 SITC Annual Meeting"](https://sotio.com/news-publications/news/sotio-showcases-new-data-on-sot201-immunocytokine-victoria-01-clinical-study-and-boxr-car-t-advancements-at-2024-sitc-annual-meeting). *Sotio*. Retrieved 2025-06-19.

1. ["PPF Group | SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences"](https://www.ppf.eu/en/press-release/sotio-expands-its-antibody-drug-conjugate-pipeline-with-exclusive-collaboration-a). *PPF Group*. Retrieved 2025-06-29.

1. Taylor, Nick Paul (2025-03-13). ["Sotio takes up option on ADCs, Boehringer inks discovery pact"](https://www.fiercebiotech.com/biotech/sotio-takes-option-adcs-boehringer-inks-discovery-pact). *www.fiercebiotech.com*. Retrieved 2025-06-29.

1. Spencer, Diana (2025-05-07). ["ADCs show best-in-class potential for treating solid tumours"](https://www.ddw-online.com/adcs-show-best-in-class-potential-for-treating-solid-tumours-34794-202505/). *Drug Discovery World (DDW)*. Retrieved 2025-06-29.

1. ["Sotio"](https://www.ppf.eu/en/our-companies/sotio). *PPF Group*. Retrieved 2022-03-15.

---
Adapted from the Wikipedia article [Sotio](https://en.wikipedia.org/wiki/Sotio) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Sotio?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.